4 Of The Best Income Stocks Around: GlaxoSmithKline plc, Standard Life Plc, SSE PLC And Centrica plc

GlaxoSmithKline plc (LON: GSK), Standard Life Plc (LON: SL), SSE PLC (LON: SSE) and Centrica PLC (LON:CNA) are four of the best dividend plays around.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Standard Life (LSE: SL) has transformed itself into an income champion over the past five years. The company’s shift to a fee-based business model has led to a tripling of cash flow generated from operations since 2010. Assets under management have risen by 50% over the same period. 

This growth has helped support the company’s dividend payout growth. Since 2011 Standard’s dividend payout has increased at a steady rate of 7% per annum. Since 2010 Standard Life has returned 147p per share to investors, including the recent special dividend and over five years the shares have produced a total return of 180%. Based on the estimated growth of the UK pension market, the next five years could see a similar performance. 

Standard Life trades at a forward P/E of 16.8 and supports a yield of 4.6%. Earnings per share are predicted to grow by 48% this year. 

Dividend concerns 

GlaxoSmithKline’s (LSE: GSK) shares have sunk to a four-year low on fears about the sustainability of the company’s dividend payout. However, to a certain extent, these concerns are unfounded.

Management has stated that the company’s dividend of 80p per share is safe for the next three years. A special dividend of 20p per share payable during the fourth quarter will take the total payout for 2015 to 100p per share, a yield of 7.9% based on Glaxo’s current share price. 

Glaxo currently trades at a forward P/E of 16.9 and supports a yield of 7.2%. Earnings per share are predicted to shrink by 21% this year. 

Slow and steady 

Last year, SSE (LSE: SSE) made a commitment to target an increase in the full-year dividend for 2015/16 of at least RPI inflation, with annual increases thereafter of at least RPI inflation also being targeted.

This is hardly the most impressive dividend policy. The RPI measure of inflation has averaged 1% this year, so investors won’t see much in the way of a dividend increase at all. 

Nevertheless, for the conservative dividend investor SSE’s dividend policy is ideal. The payout is covered 1.2 times by earnings per share and due to the nature of SSE’s business, the company has a certain degree of clarity over its revenue streams. As a result, it’s unlikely management will suddenly take an axe to the dividend. 

SSE currently trades at a forward P/E of 12.6 and supports a yield of 6.2%. Earnings per share are predicted to shrink by 10% this year.

Changing business model 

Centrica (LSE: CNA) has already cut its dividend payout once this year. However, according to City projections the new, lower payout is now covered one-and-a-half times by earnings per share, leaving plenty of room for manoeuvre. 

What’s more, management’s recent decision to scale back Centrica’s upstream business is a great move for the company. Oil & gas production is a notoriously volatile and capital intensive business. Focusing on the more predictable customer-facing side of the business should put Centrica back on the path to long-term sustainable growth.

Also, Centrica’s focus on the more predictable customer side of the business should help the company maintain and increase its dividend over time.  

Centrica currently trades at a forward P/E of 12.5 and supports a yield of 5.4%. Earnings per share are predicted to shrink by 7% this year.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Female student sitting at the steps and using laptop
Investing Articles

How much do you need in an ISA to target £8,333 a month of passive income?

Our writer explores a potential route to earning double what is today considered a comfortable retirement and all tax-free inside…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Could these 3 FTSE 100 shares soar in 2026?

Our writer identifies a trio of FTSE 100 shares he thinks might potentially have more petrol in the tank as…

Read more »

Pakistani multi generation family sitting around a table in a garden in Middlesbourgh, North East of England.
Dividend Shares

How much do you need in a FTSE 250 dividend portfolio to make £14.2k of annual income?

Jon Smith explains three main factors that go into building a strong FTSE 250 dividend portfolio to help income investors…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

275 times earnings! Am I the only person who thinks Tesla’s stock price is over-inflated?

Using conventional measures, James Beard reckons the Tesla stock price is expensive. Here, he considers why so many people appear…

Read more »

Investing Articles

Here’s what I think investors in Nvidia stock can look forward to in 2026

Nvidia stock has delivered solid returns for investors in 2025. But it could head even higher in 2026, driven by…

Read more »

Investing Articles

Here are my top US stocks to consider buying in 2026

The US remains the most popular market for investors looking for stocks to buy. In a crowded market, where does…

Read more »

Investing Articles

£20,000 in excess savings? Here’s how to try and turn that into a second income in 2026

Stephen Wright outlines an opportunity for investors with £20,000 in excess cash to target a £1,450 a year second income…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Is a 9% yield from one of the UK’s most reliable dividend shares too good to be true?

Taylor Wimpey’s recent dividend record has been outstanding, but investors thinking of buying shares need to take a careful look…

Read more »